Reduced growth hormone response to L-dopa and pyridostigmine in obesity.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The purpose of this study was to evaluate growth hormone (GH) secretion and clarify the factors influencing GH secretion in obesity.

Why It Was Studied

The researchers compared the GH response to L-dopa with or without pyridostigmine pretreatment in obese and control subjects.

Plasma glucose, insulin, insulin-like growth factor I (IGF-I) and free fatty acid (FFA) were also measured.

Who Took Part

The age groups tagged for this paper are adults, men only.

Nine obese subjects and eight controls were recruited.

How the Study Was Run

The researchers set it up as a randomized and crossover study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

What Was Measured

Plasma glucose, insulin, insulin-like growth factor I (IGF-I) and free fatty acid (FFA) were also measured.

Topics PubMed links to this paper include Body Mass Index, Fatty Acids, Nonesterified, Growth Hormone, Insulin, Levodopa, Obesity and Pituitary Gland.

What This Means in Plain Language

The paper is a randomized and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 1994 (International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.